NEW YORK (TheStreet) -- Seres Therapeutics (MCRB) shares closed trading down 25.70% to $38.19 in the second day of trading since the company's upsized initial public offering on Friday.
The Cambridge, MA-based company priced its upsized public offering of 7.43 million shares at $18 per share on Friday before closing trading up 68% to $50.49.
The company had previously said that it would offer 6.25 million shares between the $15 and $17 per share range.
Seres Therapeutics' lead development candidate, SER-109, is an oral therapeutic for the prevention of Clostridium difficile infection which affects between 85,000 and 110,000 people in the U.S.
The drug candidate is currently in Phase II trials.